BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24873792)

  • 1. (99m)Tc HYNIC-TOC imaging and 177Lu DOTA-octreotate treatment in non-iodine-concentrating dedifferentiated thyroid carcinoma metastases: an unusual alternative diagnosis.
    Basu S; Joshi A
    Clin Nucl Med; 2014 Jul; 39(7):632-4. PubMed ID: 24873792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebellar metastasis of papillary thyroid carcinoma detected with somatostatin receptor scintigraphy.
    Czepczyński R; Wyszomirska A; Gryczyńska M; Szczepanek-Parulska E; Ruchała M
    Endokrynol Pol; 2018; 69(1):24-27. PubMed ID: 29319129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma.
    Kosowicz J; Mikołajczak R; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J
    Cancer Biother Radiopharm; 2007 Oct; 22(5):613-28. PubMed ID: 17979564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 99mTc-EDDA/HYNIC-TOC in the diagnosis of differentiated thyroid carcinoma refractory to radioiodine treatment.
    Czepczyński R; Gryczyńska M; Ruchała M
    Nucl Med Rev Cent East Eur; 2016; 19(2):67-73. PubMed ID: 27479883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma.
    Czepczyński R; Parisella MG; Kosowicz J; Mikołajczak R; Ziemnicka K; Gryczyńska M; Sowiński J; Signore A
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1635-45. PubMed ID: 17530247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of scintigraphy with the use of 99mTc-HYNIC-TOC in the diagnosis of medullary thyroid carcinoma].
    Czepczyński R; Kosowicz J; Ziemnicka K; Mikołajczak R; Gryczyńska M; Sowiński J
    Endokrynol Pol; 2006; 57(4):431-5. PubMed ID: 17006849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tc-99m HYNIC-TOC scintigraphy in dedifferentiated thyroid cancer.
    Agrawal K; Patro PSS; Preetam C
    BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 30940668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 99mTc-HYNIC-TOC and HYNIC-TATE octreotide scintigraphy with FDG PET and 99mTc-MIBI in local recurrent or distant metastatic thyroid cancers.
    Sager S; Kabasakal L; Halac M; Maecke H; Uslu L; Önsel Ç; Kanmaz B
    Clin Nucl Med; 2013 May; 38(5):321-5. PubMed ID: 23531772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma.
    Teunissen JJ; Kwekkeboom DJ; Kooij PP; Bakker WH; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():107S-14S. PubMed ID: 15653659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 99mTc-EDDA/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans.
    Gabriel M; Froehlich F; Decristoforo C; Ensinger C; Donnemiller E; von Guggenberg E; Heute D; Moncayo R
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):330-41. PubMed ID: 14625664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
    Lind P; Gallowitsch HJ
    Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?
    Kohlfuerst S; Igerc I; Gallowitsch HJ; Gomez I; Kresnik E; Matschnig S; Lind P
    Thyroid; 2006 Nov; 16(11):1113-9. PubMed ID: 17123338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
    Gabriel M; Decristoforo C; Donnemiller E; Ulmer H; Watfah Rychlinski C; Mather SJ; Moncayo R
    J Nucl Med; 2003 May; 44(5):708-16. PubMed ID: 12732671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
    Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
    J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor subtype 2-mediated scintigraphy and localization using (99m)Tc-HYNIC-Tyr(3)-octreotide in human hepatocellular carcinoma-bearing nude mice.
    Li Y; Si JM; Zhang J; Du J; Wang F; Jia B
    World J Gastroenterol; 2005 Jul; 11(25):3953-7. PubMed ID: 15991301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.
    Mirzaei S; Bastati B; Lipp RW; Knoll P; Zojer N; Ludwig H
    Oncology; 2011; 80(5-6):326-9. PubMed ID: 21791941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism.
    Traub-Weidinger T; Putzer D; von Guggenberg E; Dobrozemsky G; Nilica B; Kendler D; Bale R; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1995-2001. PubMed ID: 26173620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?
    Campennì A; Pignata SA; Baldari S
    Endocrine; 2015 Nov; 50(2):516-8. PubMed ID: 25471282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.